INmune Bio (NASDAQ:INMB) Downgraded to “Sell” Rating by Wall Street Zen

INmune Bio (NASDAQ:INMB) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of INmune Bio in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, INmune Bio has a consensus rating of “Hold” and an average target price of $18.00.

INmune Bio Stock Performance

INMB stock opened at $1.91 on Friday. The company has a market capitalization of $50.77 million, a PE ratio of -0.90 and a beta of 0.91. INmune Bio has a one year low of $1.38 and a one year high of $11.64. The company’s 50 day moving average price is $1.76 and its two-hundred day moving average price is $3.11.

INmune Bio (NASDAQ:INMB) last released its earnings results on Thursday, October 30th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.07. On average, research analysts predict that INmune Bio will post -2.24 EPS for the current year.

Institutional Trading of INmune Bio

Institutional investors have recently modified their holdings of the company. Intech Investment Management LLC purchased a new position in INmune Bio during the 2nd quarter valued at about $26,000. PFG Investments LLC bought a new stake in shares of INmune Bio in the 2nd quarter worth approximately $27,000. Cary Street Partners Financial LLC purchased a new position in shares of INmune Bio during the third quarter valued at approximately $29,000. Independent Advisor Alliance purchased a new position in shares of INmune Bio during the third quarter valued at approximately $30,000. Finally, Squarepoint Ops LLC bought a new position in shares of INmune Bio during the third quarter valued at approximately $30,000. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.